Tredje AP fonden Sells 5,441 Shares of Insulet Co. (NASDAQ:PODD)

Tredje AP fonden lessened its position in shares of Insulet Co. (NASDAQ:PODD) by 50.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,442 shares of the medical instruments supplier’s stock after selling 5,441 shares during the period. Tredje AP fonden’s holdings in Insulet were worth $1,421,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PODD. SBI Securities Co. Ltd. purchased a new stake in Insulet during the 4th quarter worth about $36,000. Venturi Wealth Management LLC lifted its holdings in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 133 shares in the last quarter. SRS Capital Advisors Inc. lifted its holdings in Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial purchased a new stake in Insulet during the 4th quarter worth about $57,000. Finally, TD Private Client Wealth LLC lifted its holdings in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on PODD shares. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Stifel Nicolaus raised their price target on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Royal Bank of Canada assumed coverage on Insulet in a report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective for the company. Canaccord Genuity Group increased their price objective on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Finally, Citigroup raised their target price on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Up 4.4 %

Shares of NASDAQ:PODD opened at $255.44 on Friday. The stock has a fifty day simple moving average of $272.54 and a two-hundred day simple moving average of $254.53. The stock has a market capitalization of $17.94 billion, a price-to-earnings ratio of 44.12, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million during the quarter, compared to analysts’ expectations of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.